Bolalarda gemorragik vaskulit kechishining zamonaviy klinik-epidemiologik xususiyatlari
Annotatsiya
Kirish. Adabiyotlar ma’lumotlariga ko‘ra, gemorragik vaskulit (Henoch–Schonlein purpurasi) bolalarda eng ko‘p uchraydigan sistemali vaskulitlardan biri bo‘lib, so’nggi yillarda kasallik nafaqat maktabgacha va kichik maktab yoshida balki o’smir bolalarda ham ko’payib bormoqda va ko‘pincha respirator infeksiyalar, allergik holatlar va immun tizimidagi o‘zgarishlar bilan bog‘liq holda rivojlanmoqda. Tadqiqot maqsadi -bolalarda gemorragik vaskulit (Henoch–Schonlein purpurasi) kechishining zamonaviy klinik-epidemiologik xususiyatlarini o‘rganish. Material va usullar. Bolalardagi gemorragik vaskulitga (Henoch–Schonlein purpurasi) bagishlangan so’nggi o’n yillikda chop etilgan ilmiy adabiyot ma’lumotlari retrospektiv tahlil qilindi. Olingan ma’lumotlar yillar bo’yicha matematik tekshirildi va taqqoslandi. Natijalar va muxokama. Tadqiqot natijalari shuni ko‘rsatdiki, kasallik patogenezida immun komplekslar hosil bo‘lishi, tomir devorlarining yallig‘lanishi hamda mikrotsirkulyatsiya buzilishlari muhim o‘rin tutadi. Klinik manzarasida teri gemorragik toshmalari, bo‘g‘im, qorin sindromlari, buyrak shikastlanishi va aralash simptomlar yetakchi o’rin tutmoqda. Shuningdek, kasallikning kechishi individual xususiyatlarga ega bo‘lib, uning og‘irlik darajasi asosiy klinik simptomlari va asoratlar rivojlanishi bilan belgilanmoqda. Xulosa. Tadqiqot natijasida olingan ilmiy ma’lumotlar gemorragik vaskulitni erta aniqlash, xavf omillarini baholash hamda kasallik kechishini prognoz qilishda zamonaviy klinik-epidemiologik xususiyatlarni chuqur o‘rganish muhim ahamiyatga ega ekanligini ko‘rsatadi.
Kalit so‘zlar
Mualliflar haqida
Adabiyotlar ro'yxati
Leung AKC, Barankin B, Leong KF. Henoch–Schonlein purpura in children: an updated review. Curr Pediatr Rev. 2020;16(4):265-276.
Piram M, Madhi F, Cohen R, et al. Vaccination and risk of childhood IgA vasculitis. Pediatrics. 2018;142(5):e20180841.
Bayındır Y, Başaran O, Bilginer Y, Ozen S. Vasculitis in children. Turk Arch Pediatr. 2024;59(6):517-526.
Eryılmaz Polat S., Оzlu SG, Kargın Cakıcı E., Aydoğ O., Bulbul M. Evaluation of Epidemiological, Clinical, and Laboratory Findings in Pediatric Patients with IgA Vasculitis (Henoch-Schönlein Purpura). Turkish Journal of Clinical Pediatrics. 2024;18(2):111-116.
Tollefson MM, et al. Henoch–Schonlein purpura and systemic disease in children. Br J Dermatol. 2015;172(5):1358-1363.
Shin JI, Park JM. Henoch–Schonlein purpura nephritis in children. Kidney Res Clin Pract. 2016;35(2):63-69.
Rakhmanova L.K., Nizomutdinov A.M. Features of the course of nephrotic syndrome in children with hemorrhagic vasculitis. International Conference on Advance Research in Humanities, Sciences and Education. https://confrencea.org Hosted from Istanbul, The Turkey June 30th 2024. Р.59-60.
Saulsbury FT. Clinical update: Henoch-Schonlein purpura. Lancet. 2007;369:976-978.
Oni L, Sampath S. Childhood IgA vasculitis. Arch Dis Child. 2019;104:995-999.
Yang YH, Hung CF, Hsu CR, Wang LC, Chuang YH, Lin YT, et al. A nationwide survey of childhood IgA vasculitis. Pediatr Rheumatol. 2015;13:35.
Trapani S, Micheli A, Grisolia F, et al. Henoch-Schonlein purpura in childhood: epidemiological and clinical analysis. Clin Exp Rheumatol. 2005;23:47-53.
Davin JC, Coppo R. Henoch–Schonlein purpura nephritis in children. Nat Rev Nephrol. 2014;10:563-573.
Coppo R, Amore A. IgA vasculitis nephritis. Pediatr Nephrol. 2004;19:1161-1168.
Narchi H. Risk of long-term renal impairment in children with HSP. Arch Dis Child. 2005;90:916-920.
Weiss PF. Pediatric vasculitis. Pediatr Clin North Am. 2012;59:407-423.
Batu ED, Ozen S. Pediatric vasculitis. Curr Opin Rheumatol. 2017;29:29-38.
Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology criteria for Henoch-Schonlein purpura. Arthritis Rheum. 1990;33:1114-1121.
Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for IgA vasculitis. Ann Rheum Dis. 2010;69:798-806.
Piram M. et al., Epidemiology and risk factors of rare diseases: a cohort study on France. French Journal of Epidemiology, 2017.
Gardner-Medwin, J., & Williams, L. (2019). Prevalence of pediatric nephritis and its impact in the UK population: A population-based study. British Medical Journal, 88(4), 215-223.
Shin, J., & Kim, H. (2020). Clinical follow-up and outcomes in nephritis patients: A South Korean cohort study. Journal of Korean Clinical Nephrology, 17(2), 102-110.
Yang, Y., & Zhang, T. (2021). Abdominal syndrome and its association with chronic diseases in Chinese cohort. Chinese Medical Journal, 134(4), 98-107.
Oni, L., & Smith, B. (2023). Recurrence patterns in chronic diseases: A multi-center study in the US. American Journal of Medical Research, 28(2), 132-139.
Kilic, S., & Yildiz, M. (2024). Clinical outcomes of nephritis in Turkey: A clinical cohort study. Turkish Journal of Nephrology, 12(3), 48-55.
Nizomutdinov A.M., Rakhmanova L.K. Clinical and immunological features of the course of hemorrhagic vasculitis in children. International Conference on Advance Research in Humanities, Sciences and Education https://confrencea.org Hosted from London, The UK November 4th 2025.
Audemard-Verger A, Terrier B, Dechartres A, et al. Characteristics of IgA vasculitis. Arthritis Rheumatol. 2015;67:195-203.
Roberts PF, Waller TA, Brinker TM, et al. Henoch-Schonlein purpura: a review article. Am Fam Physician. 2007;76:697-704.
Yang Z, Wang J, Jiao F. Progress in the treatment of Henoch-Schonlein purpura in children. Int J Trop Dis Health. 2022;43(17):14-20.
Kawasaki Y. The pathogenesis and treatment of IgA vasculitis nephritis. Clin Exp Nephrol. 2011;15:648-657.
Xu J, Cai J, Hu B. Renal histopathological manifestations of IgA vasculitis nephritis. Int Immunopharmacol. 2023;116:109760.
Peruzzi L, Coppo R. IgA vasculitis nephritis in children and adults. Pediatr Nephrol. 2021;36:2615-2625.
Chen O, Zhu XB, Ren P, Wang YB. Henoch-Schonlein purpura in children: clinical analysis. World J Pediatr. 2013;9:31-35.
Heineke MH, Ballering AV, Jamin A, et al. New insights in the pathogenesis of IgA vasculitis. Autoimmun Rev. 2017;16:1246-1253.
Jennette JC, Falk RJ, Bacon PA, et al. Nomenclature of systemic vasculitides. Arthritis Rheum. 2013;65:1-11.
Kawasaki Y, Ono A, Ohara S, et al. Henoch-Schonlein purpura nephritis in childhood. Pediatr Int. 2013;55:655-659.
Zhang Y, Huang X, Wang Y. Clinical characteristics of pediatric IgA vasculitis. Pediatr Rheumatol. 2019;17:59.
Lau KK, Suzuki H, Novak J, Wyatt RJ. Pathogenesis of IgA nephropathy and IgA vasculitis. Pediatr Nephrol. 2010;25:227-241.
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402-2414.
Ruperto N, Ozen S, Pistorio A, et al. Pediatric vasculitis classification. Ann Rheum Dis. 2010;69:798-806.
Weiss PF, Feinstein JA, Luan X, et al. Effects of corticosteroids in IgA vasculitis. Pediatrics. 2010;126:674-681.
Saulsbury FT. Henoch-Schonlein purpura in children. Curr Opin Rheumatol. 2010;22:598
Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol. 2018;32:271-281.
Kim JH, Park SJ, Shin JI. Epidemiology of IgA vasculitis. Korean J Pediatr. 2015;58:1-6.
Yang YH, Yu HH, Chiang BL. The diagnosis and classification of IgA vasculitis. Autoimmun Rev. 2014;13:1065-1067.
Pohl M. Henoch-Schonlein purpura nephritis. Pediatr Nephrol. 2015;30:245-252.
Trapani S, et al. Gastrointestinal involvement in Henoch-Schonlein purpura. Clin Exp Rheumatol. 2005;23:47-53.
Kang Y, Park JS, Ha YJ, et al. Differences in clinical manifestations of IgA vasculitis. Clin Rheumatol. 2014;33:173-178.
Zhang T, Yang Y, Yu H. Clinical characteristics of recurrent IgA vasculitis. Pediatr Rheumatol. 2020;18:45.
Gan MY, Chua FZY, Chang ZY, et al. IgA vasculitis-associated nephritis. Life (Basel). 2024;14(8):930.
Li X, Chen Y, Liu X. Risk factors for renal involvement in pediatric IgA vasculitis. Kidney Int Rep. 2024;9(9):2759-2766.
Yilmaz D, Balci S. Clinical manifestations and outcomes of 420 children with Henoch-Schonlein purpura. Mod Rheumatol. 2020;30(6):1039-1046.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Qanday iqtibos keltirish kerak
